A stewardship program's retrospective evaluation of vancomycin auc24/mic and time to microbiological clearance in patients with methicillin-resistant staphylococcus aureus bacteremia and osteomyelitis

Clinical Therapeutics

Volumn 35, Issue 6, 2013, Pages 772-779

  Gawronski, Kristen M ^a   Goff, Debra A ^b   Jack Brown, ^c,d   Khadem, Tina M ^c,d   Bauer, Karri A ^b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Infectious diseases; Osteomyelitis; Pharmacodynamics; Vancomycin

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BACTERIAL CLEARANCE; FEMALE; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; OSTEOMYELITIS; RETROSPECTIVE STUDY; ADOLESCENT; ANTIBIOTIC RESISTANCE; BACTEREMIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PROGRAM EVALUATION; STAPHYLOCOCCAL INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OSTEOMYELITIS; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; YOUNG ADULT;

EID: 84879435833     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.05.008     Document Type: Article

References (29)

1. Jeffres M.N., Isakow W., Doherty J.A., et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006, 130:947-955.
2. Maor Y., Hagin M., Belausov N., Keller N., Ben-David D., Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009, 199:619-624.
3. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control. 2003;31:481-498.
4. Chua T., Moore C.L., Perri M.B., et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol 2008, 46:2345-2352.
5. Lodise T.P., McKinnon P.S. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy 2007, 27:1001-1012.
6. Klevens R.M., Morrison M.A., Nadle J., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
7. Hidayat L.K., Hsu D.I., Quist R., Shriner K.A., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
8. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., Karchmer A.W., Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005, 26:166-174.
9. Corey G.R. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin Infect Dis 2009, 48(Suppl 4):S254-S259.
10. Ben-David D., Novikov I., Mermel L.A. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection?. Infect Control Hosp Epidemiol 2009, 30:453-460.
11. Bauer K.A., West J.E., Balada-Llasat J.-M., Pancholi P., Stevenson K.B., Goff D.A. An antimicrobial stewardship program's impact. Clin Infect Dis 2010, 51:1074-1080.
12. Rybak M.J., Lomaestro B.M., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009, 29:1275-1279.
13. Rybak M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006, 42(Suppl 1):S35-S39.
14. Berthoin K., Ampe E., Tulkens P.M., Carryn S. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. Int J Antimicrob Agents 2009, 34:555-560.
15. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:e18-e55.
16. Stevens D.L. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006, 42(Suppl 1):S51-S57.
17. Moise-Broder P.A., Forrest A., Birmingham M.C., Schentag J.J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004, 43:925-942.
18. Brown J., Brown K., Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother 2012, 56:634-638.
19. Garazzino S., Aprato A., Baietto L., et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet 2008, 47:793-805.
20. Graziani A.L., Lawson L.A., Gibson G.A., Steinberg M.A., MacGregor R.R. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988, 32:1320-1322.
21. Rodvold K.A., Blum R.A., Fischer J.H., et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988, 32:848-852.
22. Rotschafer J.C., Crossley K., Zaske D.E., Mead K., Sawchuk R.J., Solem L.D. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982, 22:391-394.
23. Healy D.P., Polk R.E., Garson M.L., Rock D.T., Comstock T.J. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987, 31:393-397.
24. Golper T.A., Noonan H.M., Elzinga L., et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988, 43:565-570.
25. Lemon S.C., Roy J., Clark M.A., Friedmann P.D., Rakowski W. Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med 2003, 26:172-181.
26. Axon R., Williams M.V. Hospital readmission as an accountability measure. JAMA 2011, 305:504-505.
27. Patel N., Pai M.P., Rodvold K.A., Lomaestro B., Drusano G.L., Lodise T.P. Vancomycin: we can't get there from here. Clin Infect Dis 2011, 52:969-974.
28. Moore C.L., Osaki-Kiyan P., Haque N.Z., Perri M.B., Donabedian S., Zervos M.J. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012, 54:51-58.
29. Wong-Beringer A., Joo J., Tse E., Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011, 37:95-101.